|
|
Vaccine Comparison
|
DNA vaccine Rv1806-1807 |
pABFHc2 |
| Vaccine Information |
Vaccine Information |
- Vaccine Name: DNA vaccine Rv1806-1807
- Vaccine Ontology ID: VO_0000567
- Type: DNA vaccine
- Antigen: Rv1806 and Rv1807 (Vipond et al., 2006).
- PE20
gene engineering:
- Type: DNA vaccine construction
- Detailed Gene Information: Click Here.
- PPE31
gene engineering:
- Type: DNA vaccine construction
- Detailed Gene Information: Click Here.
- Adjuvant: DDA vaccine adjuvant
- Vector: pET11d, modified to form pET3a (Vipond et al., 2006)
- Preparation: Two bacterial strains, E. coli DH5α and Rosetta™ 2(DE3)pLysS, were propagated in Luria Bertani (LB) broth and solid medium at 37°C. An expression vector pET3a was created from pET11d expression vector (Novagen) by replacing an ampicillin cassette with kanamycin cassette, followed by restriction digestion of a HindIII site and linker insertion containing cloning sites and an N- and C-terminal 6* histidine tag. The vaccine candidate gene was amplified from M. tuberculosis using PCR and cloned into pVAX1tPA. Recombinant plasmids were generated from four encoding gene sequences and sub-cloned into pET3a prior to transformation, induction, and harvesting in E. coli Rosetta™ 2(DE3)pLysS (Vipond et al., 2006).
- Virulence: Not virulent.
- Description: Rv1806-1807 was one of three potential vaccines compared against gold-standard BCG vaccine and saline control. Rv1806-1807 induced protection in the guinea pig aerosol infection model 30 days post-challenge on the basis of reducing the bacterial burden of M tuberculosis in the lungs ( a reduction in log10 cfu of 0 . 52 and 0 . 83 in lungs and spleen , respectively , following DNA vaccination , compared with reductions of 0 . 3 and 0 . 57 , respectively , with a protein formulation) (Vipond et al., 2006).
|
- Vaccine Name: pABFHc2
- Vaccine Ontology ID: VO_0004099
- Type: DNA vaccine
- Adjuvant: Alhydrogel vaccine adjuvant
- VO ID: VO_0001241
- Description: Previous research achieved protection in a murine model using purified FHc which had been obtained from cultures of recombinant Escherichia coli and recombinant Pichia pastoris. FHc has also been expressed in a Salmonella vector and achieved protection against intoxication in a murine model. Therefore, BoNT F could constitute a good candidate for DNA vaccination, and the given study constructed a DNA vaccine based on the Hc domain of BoNT subtype F in order to investigate the utility of DNA vaccination for protection against intoxication with this subtype (Bennett et al., 2003).
- Vector: pSecTag2C (Bennett et al., 2003)
- Preparation: DNA encoding the binding domain of BoNT subtype F (FHc) was obtained as the plasmid clone pHILD4.New.FHc. Recombinant plasmid DNA was purified using Endofree Mega-Q kits (Qiagen Ltd.). Cells were analysed for expression of FHc 24 h after transfection as follows: cells were fixed in 4% paraformaldehyde at 4 °C overnight, then washed in PBS and incubated in PBS containing 2% saponin and 10% foetal calf serum (PBS-SFCS) for 2 h at 37 °C. Primary antibody, from mice immunised with pABFHc2 and boosted with recombinant FHc protein, was diluted 1:500 in PBS-SFCS and incubated with fixed cells for 1 h at 37 °C. Following washing, anti-mouse IgG conjugated to fluorescein isothiocyanate was added and the incubation was continued for a further hour at 37 °C. The cells were washed in PBS and were visualised by fluorescent confocal microscopy (Bennett et al., 2003).
- Description: Previous research achieved protection in a murine model using purified FHc which had been obtained from cultures of recombinant Escherichia coli and recombinant Pichia pastoris. FHc has also been expressed in a Salmonella vector and achieved protection against intoxication in a murine model. Therefore, BoNT F could constitute a good candidate for DNA vaccination, and the given study constructed a DNA vaccine based on the Hc domain of BoNT subtype F in order to investigate the utility of DNA vaccination for protection against intoxication with this subtype (Bennett et al., 2003).
|
| References |
References |
Vipond et al., 2006: Vipond J, Clark SO, Hatch GJ, Vipond R, Marie Agger E, Tree JA, Williams A, Marsh PD. Re-formulation of selected DNA vaccine candidates and their evaluation as protein vaccines using a guinea pig aerosol infection model of tuberculosis. Tuberculosis (Edinburgh, Scotland). 2006 May-Jul; 86(3-4); 218-24. [PubMed: 16520093].
|
Bennett et al., 2003: Bennett AM, Perkins SD, Holley JL. DNA vaccination protects against botulinum neurotoxin type F. Vaccine. 2003 Jul 4; 21(23); 3110-7. [PubMed: 12804837 ].
|
|
